Maternal haloperidol therapy associated with dyskinesia in a newborn

American Journal of Health-System Pharmacy

Volumn 60, Issue 21, 2003, Pages 2253-2255

  Collins, Kristine O ^a   Comer, Joyce B ^a  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; ANTICONVULSIVE AGENT; CLONAZEPAM; NEUROLEPTIC AGENT;

ADULT; ARTICLE; DYSKINESIA; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; LABORATORY TEST; NEWBORN; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; CASE REPORT; FETOMATERNAL TRANSFUSION; PREGNANCY; PRENATAL EXPOSURE; PSYCHOSIS;

ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CLONAZEPAM; DYSKINESIA, DRUG-INDUCED; FEMALE; HALOPERIDOL; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTIC DISORDERS;

EID: 1542682333     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.21.2253     Document Type: Article

References (15)

1. Altshuler LL, Cohen L, Szuba MP et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996; 153:592-606.
2. Slone D, Siskind V, Heinonen OP et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977; 128:486-8.
3. Cleary MF. Fluphenazine decanoate during pregnancy. Am J Psychiatry. 1977; 134:815-6 .
4. Hill RM, Desmond MM, Kay JL. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr. 1966; 69:589-95.
5. O'Connor M, Johnson GH, James DI. Intrauterine effect of phenothiazines. Med J Aust. 1981; 1:416-7.
6. Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J Perinatol. 1989; 9:170-2.
7. Tamer A, McKey R, Arias D et al. Phenothiazine-induced extrapyramidal dysfunction in the neonate. J Pediatr. 1969; 75:479-80.
8. Burke RE. Tardive dyskinesia: current clinical issues. Neurology. 1984; 34:1348-53.
9. Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry. 2000; 33(suppl):14-33.
10. Singer HS. Tardive dyskinesia: a concern for the clinician. Pediatrics. 1986; 77:553-6.
11. Auerbach JG, Hans SL, Marcus J et al. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol. 1992; 14:399-406.
12. Nielsen HC, Suvipa W, Rosenfeld CR et al. Chlorpromazine excretion by the neonate following chronic in utero exposure. Pediatr Pharmacol. 1983; 3:1-5.
13. Cohen LS, Heller VL, Rosenbaum JF. Treatment guidelines for psychotropic drug use in pregnancy. Psychosomatics. 1989; 30:25-33.
14. American Psychiatric Association. American Psychiatric Association practice guidelines: practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002; 4 (suppl):1-50.
15. American Academy of Pediatrics Committee on Drugs. Use of psychoactive medication during pregnancy and possible effects on the fetus and the newborn. Pediatrics. 2000; 105:880-7.